Sunitinib Malate Capsules 12.5mg
SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 12.5 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced and metastatic cancers. Sunitinib works by blocking specific proteins responsible for cancer cell growth, tumor progression, and the formation of blood vessels that supply nutrients to tumors.
Cancer cells rely on multiple signaling pathways to grow and spread throughout the body. Sunitinib targets these pathways by inhibiting several receptor tyrosine kinases, helping to slow tumor growth and reduce the development of new blood vessels required for cancer progression. This targeted approach makes it an important option in modern oncology treatment.
Unlike conventional chemotherapy, which may affect both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor development. This precision-based mechanism supports effective long-term disease management in eligible patients.
SUNITCAP 12.5 MG is commonly prescribed for:
Advanced Renal Cell Carcinoma (Kidney Cancer)
Metastatic Renal Cell Carcinoma
Gastrointestinal Stromal Tumors (GIST)
Pancreatic Neuroendocrine Tumors (pNET)
Advanced Solid Tumors
Targeted Cancer Therapy Programs
Precision Oncology Treatment Plans
Long-Term Cancer Management
The 12.5 mg strength is frequently used for dose adjustments, maintenance therapy, combination dosing schedules, and patients requiring lower doses based on individual treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 12.5 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require regular monitoring, including blood pressure assessments, complete blood counts, liver function testing, thyroid evaluations, and clinical examinations to ensure optimal treatment outcomes.
Due to its proven effectiveness in targeted cancer therapy, SUNITCAP 12.5 MG remains an important medicine in contemporary oncology care.
View Details
Pemetrexed Injection IP 500 mg
ALIMLIEVA 500 MG (Pemetrexed Injection IP 500 mg) is a prescription anticancer medicine containing Pemetrexed 500 mg, a chemotherapy agent widely used in the treatment of certain lung cancers and malignant pleural mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and multiplication.
Cancer cells grow and divide rapidly, requiring large amounts of folate-dependent enzymes for survival. Pemetrexed blocks several key enzymes involved in the synthesis of nucleic acids, thereby slowing cancer cell growth and promoting cancer cell death. This targeted action helps control tumor progression and improve treatment outcomes.
ALIMLIEVA 500 MG is commonly prescribed for patients with Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma, either as a single agent or in combination with other anticancer medicines such as platinum-based chemotherapy. It may also be used as maintenance therapy in eligible patients to help delay disease progression.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
ALIMLIEVA 500 MG is commonly used for:
Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Squamous NSCLC
Maintenance Therapy in NSCLC
Malignant Pleural Mesothelioma
Advanced Lung Cancer Treatment
Combination Chemotherapy Programs
Oncology Treatment Protocols
Long-Term Cancer Management
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 500 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with regular blood tests and clinical monitoring to minimize side effects and optimize treatment outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 500 MG remains an important medicine in modern cancer care.
View Details
Pemetrexed Injection IP 100mg
ALIMLIEVA 100 MG (Pemetrexed Injection IP 100 mg) is a prescription anticancer medicine containing Pemetrexed 100 mg, an antifolate chemotherapy agent used in the treatment of specific cancers, particularly Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma. It belongs to a class of medicines known as Antifolate Antineoplastic Agents, which work by interfering with the production of DNA and RNA required for cancer cell growth and survival.
Cancer cells require folate-dependent enzymes to replicate and spread. Pemetrexed blocks multiple enzymes involved in the synthesis of nucleic acids, thereby preventing cancer cells from multiplying and promoting their destruction. This mechanism helps slow disease progression and improve treatment outcomes.
ALIMLIEVA 100 MG is commonly used as part of combination chemotherapy regimens, maintenance therapy programs, and individualized dosing schedules. The 100 mg strength allows oncologists to accurately adjust treatment doses according to a patient’s body surface area (BSA), treatment protocol, and clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
ALIMLIEVA 100 MG is commonly prescribed for:
Non-Small Cell Lung Cancer (NSCLC)
Advanced Non-Squamous NSCLC
Maintenance Therapy in NSCLC
Malignant Pleural Mesothelioma
Advanced Lung Cancer Treatment
Combination Chemotherapy Programs
Oncology Treatment Protocols
Individualized Cancer Dosing Regimens
Manufactured according to stringent pharmaceutical quality standards, ALIMLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Pemetrexed therapy generally require supplementation with folic acid and vitamin B12, along with routine blood tests and medical monitoring to reduce treatment-related side effects and optimize outcomes.
Due to its established efficacy in thoracic oncology, ALIMLIEVA 100 MG remains an important medicine in modern cancer care.
View Details
Oxaliplatin Injection USP 100mg
OXALIEVA 100 MG (Oxaliplatin Injection USP 100 mg) is a prescription anticancer medicine containing Oxaliplatin 100 mg, a platinum-based chemotherapy agent widely used in the treatment of colorectal cancer and other gastrointestinal malignancies. Oxaliplatin belongs to a class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Cancer cells divide rapidly and depend on intact DNA for survival and replication. Oxaliplatin forms cross-links within DNA strands, disrupting the genetic material of cancer cells and ultimately leading to cell death. This mechanism helps slow tumor growth and supports effective cancer management.
OXALIEVA 100 MG is commonly used as part of combination chemotherapy regimens, particularly with fluoropyrimidine-based therapies such as 5-Fluorouracil (5-FU) and Leucovorin. It plays a significant role in both adjuvant and metastatic treatment settings.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
OXALIEVA 100 MG is commonly prescribed for:
Colorectal Cancer
Advanced Colorectal Cancer
Metastatic Colorectal Cancer
Adjuvant Colon Cancer Treatment
Gastrointestinal Cancers
Combination Chemotherapy Programs
Oncology Treatment Protocols
Long-Term Cancer Management
Manufactured according to stringent pharmaceutical quality standards, OXALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Oxaliplatin therapy require regular blood tests, liver and kidney function monitoring, and neurological assessments to ensure safe and effective treatment.
Due to its established efficacy in colorectal cancer management, OXALIEVA 100 MG remains an important medicine in modern oncology practice.
View Details
Oxaliplatin Injection USP 50mg
OXALIEVA 50 MG (Oxaliplatin Injection USP 50 mg) is a prescription anticancer medicine containing Oxaliplatin 50 mg, a platinum-based chemotherapy agent widely used in the treatment of colorectal cancer and certain other gastrointestinal malignancies. Oxaliplatin belongs to the class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells and preventing them from growing and multiplying.
Cancer cells divide rapidly and require healthy DNA to survive and spread. Oxaliplatin forms cross-links within DNA strands, disrupting the genetic material of cancer cells and ultimately causing cancer cell death. This action helps slow tumor progression and supports effective disease management.
OXALIEVA 50 MG is commonly administered as part of combination chemotherapy regimens such as FOLFOX (Oxaliplatin, Leucovorin, and 5-Fluorouracil), which is widely used in the treatment of colon and rectal cancers. The 50 mg strength allows healthcare professionals to tailor treatment doses according to individual patient requirements and treatment protocols.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
OXALIEVA 50 MG is commonly prescribed for:
Colorectal Cancer
Colon Cancer
Rectal Cancer
Metastatic Colorectal Cancer
Adjuvant Colon Cancer Therapy
Gastrointestinal Malignancies
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, OXALIEVA 50 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Oxaliplatin therapy require regular blood tests, liver and kidney function monitoring, and neurological evaluations to ensure safe and effective treatment.
Due to its proven efficacy in colorectal cancer treatment, OXALIEVA 50 MG remains an important component of modern oncology care.
View Details
Cisplatin Injection IP 50mg
CISLIEVA 50 MG (Cisplatin Injection IP 50 mg) is a prescription anticancer medicine containing Cisplatin 50 mg, a platinum-based chemotherapy agent widely used in the treatment of various solid tumors. Cisplatin belongs to the class of medicines known as Platinum Coordination Compounds, which work by damaging the DNA of cancer cells, thereby preventing their growth, replication, and spread.
Cisplatin is one of the most extensively used chemotherapy medicines in oncology and has been a cornerstone of cancer treatment for several decades. It interferes with cancer cell DNA by forming cross-links within DNA strands, making it difficult for cancer cells to divide and survive. This ultimately leads to cancer cell death and helps control tumor progression.
CISLIEVA 50 MG is commonly prescribed as part of single-agent or combination chemotherapy regimens for a wide range of cancers. It is frequently used in treatment protocols for testicular cancer, ovarian cancer, bladder cancer, lung cancer, head and neck cancer, cervical cancer, and other solid tumors.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
CISLIEVA 50 MG is commonly used for:
Testicular Cancer
Ovarian Cancer
Bladder Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Head and Neck Cancer
Cervical Cancer
Esophageal Cancer
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CISLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Cisplatin therapy require regular monitoring of kidney function, liver function, hearing, electrolyte levels, and blood counts to ensure safe and effective treatment.
Due to its broad clinical utility and proven effectiveness, CISLIEVA 50 MG remains a key medicine in modern cancer treatment.
View Details
Cisplatin Injection IP 10 MG
CISLIEVA 10 MG (Cisplatin Injection IP 10 mg) is a prescription anticancer medicine containing Cisplatin 10 mg, a platinum-based chemotherapy agent used in the treatment of a wide range of solid tumors. Cisplatin belongs to the class of Platinum Coordination Compounds, which work by damaging the DNA of cancer cells, preventing them from growing, dividing, and spreading throughout the body.
Cisplatin is one of the most established and effective chemotherapy medicines in oncology. It acts by forming cross-links within cancer cell DNA, disrupting normal cellular replication and triggering cancer cell death. This mechanism helps control tumor growth and supports improved treatment outcomes in various cancers.
CISLIEVA 10 MG is commonly administered as part of combination chemotherapy regimens and is frequently used alongside other anticancer medicines or radiation therapy depending on the patient's diagnosis and treatment plan.
The 10 mg presentation is often utilized for individualized dosing, dose adjustments, combination therapy protocols, and treatment schedules requiring precise dose calculations.
CISLIEVA 10 MG is commonly prescribed for:
Testicular Cancer
Ovarian Cancer
Bladder Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Head and Neck Cancer
Cervical Cancer
Esophageal Cancer
Gastric Cancer
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CISLIEVA 10 MG is designed to deliver consistent quality, safety, and therapeutic effectiveness.
Patients receiving Cisplatin therapy require regular monitoring of kidney function, blood counts, electrolyte levels, and hearing assessments to ensure optimal treatment outcomes and safety.
Due to its proven efficacy across multiple cancer types, CISLIEVA 10 MG remains an important component of modern oncology treatment protocols.
View Details
Carboplatin Injection IP 450mg
CARBOLIEVA 450 MG (Carboplatin Injection IP 450 mg) is a prescription anticancer medicine containing Carboplatin 450 mg, a platinum-based chemotherapy agent used in the treatment of various cancers. Carboplatin belongs to the class of Platinum Coordination Compounds, which work by damaging the DNA of cancer cells and preventing their growth, multiplication, and spread.
Carboplatin is widely used in oncology because of its proven effectiveness and comparatively favorable safety profile when compared to some other platinum-based chemotherapy agents. It interferes with cancer cell DNA by forming cross-links that prevent proper DNA replication and transcription, ultimately leading to cancer cell death.
CARBOLIEVA 450 MG is commonly prescribed as a single-agent therapy or as part of combination chemotherapy regimens for the treatment of ovarian cancer, lung cancer, head and neck cancer, breast cancer, and several other solid tumors.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
CARBOLIEVA 450 MG is commonly used for:
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Head and Neck Cancer
Breast Cancer
Cervical Cancer
Endometrial Cancer
Germ Cell Tumors
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CARBOLIEVA 450 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Carboplatin therapy require routine monitoring of blood counts, kidney function, liver function, and overall health status to ensure optimal treatment outcomes.
Due to its broad clinical utility and established efficacy, CARBOLIEVA 450 MG remains an important medicine in modern oncology care.
View Details
Carboplatin Injection IP 150mg
CARBOLIEVA 150 MG (Carboplatin Injection IP 150 mg) is a prescription anticancer medicine containing Carboplatin 150 mg, a platinum-based chemotherapy agent widely used in the treatment of various solid tumors. Carboplatin belongs to the class of Platinum Coordination Compounds, which work by interfering with the DNA of cancer cells, preventing their growth, multiplication, and spread.
Carboplatin is a well-established chemotherapy medicine used in modern oncology for its effectiveness against multiple cancer types and its predictable safety profile. The medicine forms cross-links within cancer cell DNA, disrupting DNA replication and cellular function, ultimately leading to cancer cell death.
CARBOLIEVA 150 MG is commonly prescribed either as a single-agent therapy or as part of combination chemotherapy regimens for cancers such as ovarian cancer, lung cancer, breast cancer, cervical cancer, and other advanced solid tumors.
The 150 mg strength provides flexibility in chemotherapy dosing and allows oncologists to tailor treatment according to the patient’s body surface area (BSA), kidney function, and treatment protocol.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
CARBOLIEVA 150 MG is commonly used for:
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Breast Cancer
Cervical Cancer
Head and Neck Cancer
Endometrial Cancer
Germ Cell Tumors
Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, CARBOLIEVA 150 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Carboplatin therapy require routine monitoring of blood counts, kidney function, liver function, and overall health status to support safe and effective treatment.
Due to its established efficacy across multiple cancer indications, CARBOLIEVA 150 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel (Protein Bound Particles) for Injection Suspension 100 MG
NAB-PACLIEVA 100 MG (Paclitaxel Protein-Bound Particles for Injection Suspension 100 mg) is a prescription anticancer medicine containing Paclitaxel 100 mg formulated as albumin-bound (protein-bound) nanoparticles for intravenous administration. This advanced formulation is designed to improve the delivery of Paclitaxel to tumor tissues while eliminating the need for certain solvent-based excipients used in conventional paclitaxel formulations.
Paclitaxel belongs to a class of medicines known as Taxane Antineoplastic Agents, which work by interfering with the normal function of microtubules inside cancer cells. By stabilizing microtubules and preventing their breakdown, Paclitaxel inhibits cell division and ultimately leads to cancer cell death.
NAB-PACLIEVA 100 MG is widely used in the treatment of several cancers, including breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. It may be administered alone or in combination with other anticancer medicines depending on the treatment protocol and patient condition.
The albumin-bound technology enhances drug transport and allows effective chemotherapy delivery without the need for certain solvent-related premedications commonly required with conventional Paclitaxel formulations.
NAB-PACLIEVA 100 MG is commonly prescribed for:
Metastatic Breast Cancer
Advanced Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Pancreatic Cancer
Locally Advanced Pancreatic Cancer
Combination Chemotherapy Programs
Oncology Treatment Protocols
Advanced Solid Tumors
Manufactured according to stringent pharmaceutical quality standards, NAB-PACLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving treatment require regular monitoring of blood counts, liver function, and overall health status throughout therapy.
Due to its proven efficacy and innovative formulation, NAB-PACLIEVA 100 MG remains an important option in modern oncology treatment.
View Details
Fulvestrant Injection 250 MG
FALSOLIEVA 250 MG (Fulvestrant Injection 250 mg) is a prescription anticancer medicine containing Fulvestrant 250 mg, a hormonal therapy used primarily in the treatment of hormone receptor-positive (HR-positive) breast cancer in postmenopausal women. Fulvestrant belongs to a class of medicines known as Selective Estrogen Receptor Degraders (SERDs), which work by blocking and reducing estrogen receptors on cancer cells.
Many breast cancer cells depend on estrogen to grow and multiply. Fulvestrant binds to estrogen receptors and accelerates their degradation, reducing the ability of cancer cells to receive estrogen signals. This action helps slow or stop the growth of hormone-sensitive breast cancer cells.
FALSOLIEVA 250 MG is commonly used in the treatment of advanced breast cancer, locally advanced breast cancer, and metastatic breast cancer. It may be prescribed alone or in combination with targeted therapies, depending on the patient's clinical condition and treatment plan.
The medicine is administered as an intramuscular injection under the supervision of qualified healthcare professionals experienced in oncology treatment.
FALSOLIEVA 250 MG is commonly prescribed for:
Hormone Receptor-Positive (HR-Positive) Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Estrogen Receptor-Positive (ER-Positive) Breast Cancer
Endocrine Therapy for Breast Cancer
Combination Targeted Therapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, FALSOLIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Fulvestrant therapy require regular medical evaluations and monitoring to assess treatment response and overall health status.
Due to its proven effectiveness in hormone-sensitive breast cancer, FALSOLIEVA 250 MG remains an important component of modern breast cancer management.
View Details
Docetaxel Injection IP 120 MG
DOCELIEVA 120 MG (Docetaxel Injection IP 120 mg) is a prescription anticancer medicine containing Docetaxel 120 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Docetaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth.
Docetaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This disruption inhibits cancer cell replication and ultimately leads to cancer cell death. Due to its proven efficacy, Docetaxel is an important component of modern oncology treatment protocols.
DOCELIEVA 120 MG is commonly prescribed for the treatment of breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric cancer, and head and neck cancers. It may be administered as a single-agent therapy or in combination with other anticancer medicines depending on the treatment plan.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in cancer treatment.
DOCELIEVA 120 MG is commonly used for:
Breast Cancer
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Prostate Cancer
Gastric Cancer
Head and Neck Cancer
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, DOCELIEVA 120 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Docetaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, DOCELIEVA 120 MG remains a key medicine in modern cancer management.
View Details
